Boehringer Ingelheim Press Releases

New long-term data reinforce safety profile of Pradaxa^® for stroke prevention in AF

Boehringer Ingelheim’s investigational all-oral interferon-free combination achieved 95% viral cure rates in genotype-1b hepatitis C patients

Boehringer Ingelheim and Eli Lilly and Company Alliance to Feature 34 Presentations in Type 1 and Type 2 Diabetes at the 73rd American Diabetes Association® Scientific Sessions

Boehringer Ingelheim’s investigational faldaprevir⁺ achieved viral cure in 88% of treatment-naïve hepatitis C patients in Asia

Boehringer Ingelheim pioneers biopharmaceuticals move to China

LUME-Lung 1: Nintedanib* plus chemotherapy extends the life of lung cancer patients with adenocarcinoma

Superiority of afatinib* over comparator chemotherapy for patients with EGFR mutation-positive advanced lung cancer is reinforced by second Phase III study

New European survey highlights ischaemic stroke protection as treatment priority for patients with atrial fibrillation

Boehringer Ingelheim and Eli Lilly & Company launch type 2 diabetes educational game, "Complications Combat"

Boehringer Ingelheim responds to FDA warning letter

Wireless Pill Bottle Wins Healthcare Innovation World Cup

Phase III results: tiotropium* Respimat® effective in symptomatic asthma patients despite at least ICS†/LABA‡ independent of their age, allergic status, smoking status and bronchodilator response

Change in the Board of Managing Directors at Boehringer Ingelheim

ASCO 2013: Boehringer Ingelheim to present highly anticipated new Phase III results for front-runner compounds afatinib* and nintedanib* in first- and second-line NSCLC treatment

ASCO 2013: New Phase III data reveal targeted treatment with afatinib* or with nintedanib* improves progression-free survival in patients with advanced NSCLC

Boehringer Ingelheim joins Structural Genomics Consortium - for further research into uncurable diseases

Boehringer Ingelheim Announces a Strong 2012 Performance in China

Boehringer Ingelheim consistently continues growth phase in financial year 2012